Skip to main content
NCBI home page
AAPS PharmSciTech logoLink to AAPS PharmSciTech
. 2014 Mar 30;7(4):E118–E122. doi: 10.1208/pt070499

Aggregation of recombinant human interferon alpha 2b in solution: Technical note

Llamil Ruiz 1,✉, Kethia Aroche 1, Nuria Reyes 1
PMCID: PMC2750336  PMID: 17285753

Summary and Conclusions

Sodium phosphate buffer increased the aggregation of rhIFN-α2b in the range of 1.55 to 1.8103 day−1, as determined by SDS/PAGE under reduced and nonreduced conditions. In contrast, sodium citrate buffer decreased the aggregation rate of this cytokine, as compared with those samples in sodium phosphate buffer. Results from sodium citrate-phosphate buffer were very similar to those obtained with sodium citrate solutions.

On the other hand, EDTA Na2×2H2O reduced the aggregation rate of rhIFN-α2b, showing an aggregation kinetic constant in the range of 0.52 to 0.75×103 day−1. Polysorbates 20 and 80 were less effective than the chelating agent in preventing this degradation pathway.

Additionally, metal ions (Zn2+ and Cu2+) increased the aggregation kinetic constant of rhIFN-α2b, probably through undetermined metal-catalyzing reactions.

Taken together, these data can be useful for the development of new formulations containing rhIFN-α2b as an active ingredient.

Full Text

The Full Text of this article is available as a PDF (246.8 KB).

References

  • 1.Manning MC, Patel K, Borchardt RT. Stability of protein pharmaceuticals. Pharm Res. 1989;6:903–918. doi: 10.1023/A:1015929109894. [DOI] [PubMed] [Google Scholar]
  • 2.Bordens R, Grossberg SE, Trotta PP, Nagabhushan TL. Molecular and biologic characterization of recombinant interferon-alpha2b. Semin Oncol. 1997;24:S9-41–S9-51. [PubMed] [Google Scholar]
  • 3.Sasson A. Biotechnology applied to the production of pharmaceuticals and vaccines. Havana, Cuba: Elfos Scientiae; 1998. [Google Scholar]
  • 4.Yuen P, Kline D, inventors; Schering Corporation, assignee. Stable aqueous alpha interferon solution formulations. US patent 5 766 582. June 16. 1998.
  • 5.Kirkwood J. Cancer immunotherapy: the interferon-alpha experience. Semin Oncol. 2002;29:18–26. doi: 10.1053/sonc.2002.33078. [DOI] [PubMed] [Google Scholar]
  • 6.Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339:1493–1499. doi: 10.1056/NEJM199811193392102. [DOI] [PubMed] [Google Scholar]
  • 7.Ruiz L, Reyes N, Duany L, Franco A, Aroche K, Rando EH. Long-term stabilization of recombinant human interferon α 2b in aqueous solution without serum albumin. Int J Pharm. 2003;264:57–72. doi: 10.1016/S0378-5173(03)00388-0. [DOI] [PubMed] [Google Scholar]
  • 8.Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm. 1999;185:129–188. doi: 10.1016/S0378-5173(99)00152-0. [DOI] [PubMed] [Google Scholar]
  • 9.Beldarrain A, Cruz C, Cruz O, Navarro M, Gil M. Purification and conformational properties of a human interferon alpha 2b produced in Escherichia coli. Biotechnol Appl Biochem. 2001;33:173–182. doi: 10.1042/BA20010001. [DOI] [PubMed] [Google Scholar]
  • 10.Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  • 11.Sigarroa A. Biometry and Experimental Design. Havana, Cuba: Pueblo y Educación; 1985. pp. 383–396. [Google Scholar]
  • 12.Morehead H, Johnston PD, Wetzel R. Roles of the 29–138 disulfide bond of subtype A of human alpha interferon in its antiviral activity and conformational stability. Biochemistry. 1984;23:2500–2507. doi: 10.1021/bi00306a028. [DOI] [PubMed] [Google Scholar]
  • 13.Chen BL, Arakawa T, Morris CF, Kenney WC, Wells CM, Pitt CG. Aggregation pathway of recombinant human keratinocyte growth factor and its stabilization. Pharm Res. 1994;11:1581–1587. doi: 10.1023/A:1018905720139. [DOI] [PubMed] [Google Scholar]
  • 14.Fransson J, Hagman A. Oxidation of human insulin-like growth factor I in formulation studies, II: effects of oxygen, visible light, and phosphate on methionine oxidation in aqueous solution and evaluation of possible mechanisms. Pharm Res. 1996;13:1476–1481. doi: 10.1023/A:1016015226211. [DOI] [PubMed] [Google Scholar]
  • 15.Fields G, Alonso D, Stiger D, Dill K. Theory for the aggregation of proteins and copolymers. J Phys Chem. 1992;96:3974–3981. doi: 10.1021/j100189a013. [DOI] [Google Scholar]
  • 16.Speed MA, Wang DIC, King J. Specific aggregation of partially folded polypeptide chains: the molecular basis of inclusion body composition. Nat Biotechnol. 1996;14:1283–1287. doi: 10.1038/nbt1096-1283. [DOI] [PubMed] [Google Scholar]
  • 17.Cleland JL, Powel MF, Shire SJ. The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit Rev Ther Drug Carrier Syst. 1993;10:307–377. [PubMed] [Google Scholar]
  • 18.Bam NB, Cleland JL, Yang J, et al. Tween protects recombinant human growth hormone against agitation-induced damage via hydrophobic interactions. J Pharm Sci. 1998;87:1554–1559. doi: 10.1021/js980175v. [DOI] [PubMed] [Google Scholar]
  • 19.Ha E, Wang W, Wang YJ. Peroxide formation in polysorbate 80 and protein stability. J Pharm Sci. 2002;91:2252–2264. doi: 10.1002/jps.10216. [DOI] [PubMed] [Google Scholar]
  • 20.Reyes N, Ruiz LI, Aroche K, Gerónimo H, Brito O, Hardy E. Stability of Ala 125 recombinant human interleukin-2 in solution. J Pharm Pharmacol. 2005;57:31–37. doi: 10.1211/0022357055182. [DOI] [PubMed] [Google Scholar]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists

RESOURCES